Santaris, BMS Partner To Develop Therapeutics Targeting miRNA
This article was originally published in The Pink Sheet Daily
In the latest of a handful of big pharma RNA partnerships, Bristol-Myers and Santaris have entered into a broad discovery and development deal. For the biotech, it brings a new partner into the string of deals that continue to be its main source of capital.
You may also be interested in...
Following a Phase III disappointment with its lead anticancer candidate, Germany’s Isarna Therapeutics has garnered new funding to advance its preclinical pipeline of oligonucleotides targeting TGF-beta.
As “The Pink Sheet” team heads to BIO’s annual partnering convention in Chicago, the Russian government rejects Abbott’s bid for NGO Petrovax. Plus news on deals between Roche and Ascletis, Lilly and Siemens, and Santaris and Bristol-Myers.
The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.